Citadel Advisors’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,976
Closed -$111K 13868
2025
Q4
$147K Sell
11,976
-96,815
-89% -$1.58M ﹤0.01% 11340
2025
Q3
$2.23M Sell
108,791
-73,555
-40% -$1.17M ﹤0.01% 5858
2025
Q2
$2.46M Buy
182,346
+110,471
+154% +$1.21M ﹤0.01% 5333
2025
Q1
$622K Buy
71,875
+30,826
+75% +$188K ﹤0.01% 7994
2024
Q4
$199K Sell
41,049
-34,729
-46% -$194K ﹤0.01% 10469
2024
Q3
$585K Sell
75,778
-26,675
-26% -$237K ﹤0.01% 7931
2024
Q2
$1.02M Buy
102,453
+50,252
+96% +$552K ﹤0.01% 6528
2024
Q1
$634K Sell
52,201
-60,044
-53% -$871K ﹤0.01% 7863
2023
Q4
$1.61M Buy
112,245
+59,206
+112% +$568K ﹤0.01% 5768
2023
Q3
$413K Sell
53,039
-37,442
-41% -$407K ﹤0.01% 8495
2023
Q2
$1.29M Sell
90,481
-98,104
-52% -$1.4M ﹤0.01% 5942
2023
Q1
$2.76M Buy
188,585
+31,409
+20% +$526K ﹤0.01% 4779
2022
Q4
$2.64M Buy
157,176
+58,498
+59% +$1.01M ﹤0.01% 4967
2022
Q3
$1.46M Buy
+98,678
New +$1.95M ﹤0.01% 6204
2022
Q2
Sell
-52,488
Closed -$1.56M 13753
2022
Q1
$1.98M Buy
+52,488
New +$2.32M ﹤0.01% 6103
2021
Q4
Sell
-12,192
Closed -$924K 14466
2021
Q3
$1.04M Sell
12,192
-5,935
-33% -$372K ﹤0.01% 8049
2021
Q2
$1.12M Buy
18,127
+11,103
+158% +$565K ﹤0.01% 8069
2021
Q1
$342K Sell
7,024
-20,744
-75% -$1M ﹤0.01% 10538
2020
Q4
$865K Buy
+27,768
New +$680K ﹤0.01% 7095

Other funds holding OPRX

Citadel Advisors's OPRX Position: Q1 2026 in Review

Citadel Advisors sold out of OptimizeRx (OPRX) in Q1 2026, closing a stake of 11,976 shares — an estimated $111K sold.

Citadel Advisors first reported a position in OPRX in Q4 2020 and held it in 19 quarters. The position peaked at $2.76M in Q1 2023. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Citadel Advisors reported no remaining OptimizeRx position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,976 OptimizeRx shares in Q1 2026, an estimated $111K.
  • Citadel Advisors first reported a position in OptimizeRx in Q4 2020 and held it in 19 quarters.
  • Citadel Advisors's OptimizeRx position peaked at $2.76M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.